Cancel
See Linkedin
Known information
- Has 28 years of experience in biopharmaceutical development and manufacturing.
- Previously served as Vice President, Global Biopharmaceutical Development at Incyte Corporation.
- Was responsible for CMC development and supply chain activities for the large molecule pipeline at Incyte Corporation.
- Held various positions at Oncobiologics (now Outlook Therapeutics), Bristol Myers Squibb, and Jacobs Engineering.
- Earned a Master of Engineering degree in Chemical Engineering from Lehigh University.
About Akero Therapeutics
Akero Therapeutics, founded in 2017 and headquartered in South San Francisco, pioneers novel therapies for serious metabolic diseases, focusing on Efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH). EFX, an Fc-FGF21 fusion protein, has shown potential in reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipids.
Report inaccurate information
